Company intelligence / Profile preview

Original Drug Port Pharmaceutical

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Original Drug Port Pharmaceutical is a China-based biotechnology company focused on the research and development of innovative small molecule drugs, particularly in the field of anti-infectives. The company's primary focus is on developing treatments for chronic Hepatitis B (HBV), aiming to provide more effective therapeutic options for patients. Their lead programs involve novel inhibitors targeting viral replication processes. In addition to its internal pipeline, the company provides pharmaceutical technology services and research support within the Chinese life sciences ecosystem.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Original Drug Port Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Original Drug Port Pharmaceutical.

Explore the full profile